Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – Here’s What Happened

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Friday . Approximately 9,615 shares traded hands during mid-day trading, an increase of 38% from the previous session’s volume of 6,973 shares.The stock last traded at $18.54 and had previously closed at $20.40.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. B. Riley Financial started coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price for the company. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price target on the stock. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. BTIG Research reiterated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The stock’s 50-day moving average is $18.81 and its two-hundred day moving average is $22.70.

Hedge Funds Weigh In On Ascentage Pharma Group International

Hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the third quarter worth $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the second quarter valued at $391,000. Finally, UBS Group AG lifted its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.